Ronja Capital AS, a legal person closely associated with a person discharging
managerial responsibility in Arctic Bioscience, has today transferred 3,087,999
shares in Arctic Bioscience to Ronja Capital Investment AS at an average price
of NOK 13,50 per share. Both companies are controlled by Roger Halsebakk and
closely related to board member Tore Tønseth in Arctic Bioscience AS.

After the transaction Ronja Capital AS holds 0 shares and Ronja Capital
Investment AS holds 3,087,999 shares in Arctic Bioscience AS, corresponding to
an ownership of 12.17 % of the issued and outstanding share capital in Arctic
Bioscience AS.

The transaction is related to internal restructuring of Ronja Capital AS.

Member of the Board of Directors, Tore A. Tønseth, is Investment Director at
Ronja Capital AS.

Please refer to the attached notification of trading for further details.

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
§ 5-12.

For more information, please contact:

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.